Harada H - Search Results

1

Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.

Harada Y, Harada H. Harada Y, et al. Among authors: harada h. J Cell Physiol. 2009 Jul;220(1):16-20. doi: 10.1002/jcp.21769. J Cell Physiol. 2009. PMID: 19334039 Review.

2

A specific chromosome abnormality of t(4;12)(q11-12;p13) in CD7+ acute leukaemia.

Harada H, Asou H, Kyo T, Asaoku H, Iwato K, Dohy H, Oda K, Harada Y, Kita K, Kamada N. Harada H, et al. Among authors: harada y. Br J Haematol. 1995 Aug;90(4):850-4. doi: 10.1111/j.1365-2141.1995.tb05206.x. Br J Haematol. 1995. PMID: 7545425

3

Characterization of acute leukemia with t(4;12).

Harada H, Harada Y, Eguchi M, Dohy H, Kamada N. Harada H, et al. Among authors: harada y. Leuk Lymphoma. 1997 Mar;25(1-2):47-53. doi: 10.3109/10428199709042495. Leuk Lymphoma. 1997. PMID: 9130613

4

Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia.

Harada H, Harada Y, Tanaka H, Kimura A, Inaba T. Harada H, et al. Among authors: harada y. Blood. 2003 Jan 15;101(2):673-80. doi: 10.1182/blood-2002-04-1010. Epub 2002 Sep 5. Blood. 2003. PMID: 12393679

5

Expression and functional analysis of granulocyte colony-stimulating factor receptors on CD34++ cells in patients with myelodysplastic syndrome (MDS) and MDS-acute myeloid leukaemia.

Sultana TA, Harada H, Ito K, Tanaka H, Kyo T, Kimura A. Sultana TA, et al. Among authors: harada h. Br J Haematol. 2003 Apr;121(1):63-75. doi: 10.1046/j.1365-2141.2003.04261.x. Br J Haematol. 2003. PMID: 12670333

6

High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia.

Harada H, Harada Y, Niimi H, Kyo T, Kimura A, Inaba T. Harada H, et al. Among authors: harada y. Blood. 2004 Mar 15;103(6):2316-24. doi: 10.1182/blood-2003-09-3074. Epub 2003 Nov 13. Blood. 2004. PMID: 14615365

7

Point mutations in the AML1/RUNX1 gene associated with myelodysplastic syndrome.

Harada H, Harada Y. Harada H, et al. Among authors: harada y. Crit Rev Eukaryot Gene Expr. 2005;15(3):183-96. doi: 10.1615/critreveukargeneexpr.v15.i3.10. Crit Rev Eukaryot Gene Expr. 2005. PMID: 16390315 Review.

8

Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.

Niimi H, Harada H, Harada Y, Ding Y, Imagawa J, Inaba T, Kyo T, Kimura A. Niimi H, et al. Among authors: harada h, harada y. Leukemia. 2006 Apr;20(4):635-44. doi: 10.1038/sj.leu.2404136. Leukemia. 2006. PMID: 16467864

9

Implications of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome (MDS): future molecular therapeutic directions for MDS.

Harada H, Harada Y, Kimura A. Harada H, et al. Among authors: harada y. Curr Cancer Drug Targets. 2006 Sep;6(6):553-65. doi: 10.2174/156800906778194595. Curr Cancer Drug Targets. 2006. PMID: 17017876 Review.

10

Mutations of the HIPK2 gene in acute myeloid leukemia and myelodysplastic syndrome impair AML1- and p53-mediated transcription.

Li XL, Arai Y, Harada H, Shima Y, Yoshida H, Rokudai S, Aikawa Y, Kimura A, Kitabayashi I. Li XL, et al. Among authors: harada h. Oncogene. 2007 Nov 8;26(51):7231-9. doi: 10.1038/sj.onc.1210523. Epub 2007 May 28. Oncogene. 2007. PMID: 17533375

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results